Stockreport

Keros Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Keros Therapeutics, Inc. - common stock  (KROS) 
PDF LEXINGTON, Mass., April 13, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the disco [Read more]